|Articles|November 7, 2005

PharmRep06Cal

External Link - article-196842.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

ByNicholas Jacobus

August 26th 2026

Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera

ByNicholas Jacobus

August 26th 2026

The FDA approved daraxonrasib (Rasonque), the first RAS-directed therapy for previously treated metastatic pancreatic adenocarcinoma, after a phase 3 trial showed median overall survival of 13.2 months versus 6.7 months with chemotherapy. Credit: Stock.Adobe.com/Sebastian Kaulitzki

FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer

ByPharmExec Staff

August 26th 2026

Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report

ByNicholas Jacobus

August 26th 2026

Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera Lead Immunology Asset

ByNicholas Jacobus

August 26th 2026

PharmRep06Cal

Related Content

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera

FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer

Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report

Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera Lead Immunology Asset

Trending on PharmExec

Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report

FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

The Retailization of Medicare Advantage: What Costco’s Entry Means for Pharma

Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations